Michael J. McElhaugh is CEO & President at Arbutus Biopharma Corp (ABUS). They have made 3 open-market trades across 1 company since 2020, most recently 2025-02-14.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABUS | 1,658,003 | $8.4M |
Shares reported on the most recent Form 4, priced at the 2025-02-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABUS | SELL · 10b5-1 | 2025-02-04 | 2025-02-05 | $3.28 | $156K | -5.9% | -7.3% | -7.0% |
| ABUS | SELL · 10b5-1 | 2024-02-02 | 2024-02-05 | $2.31 | $23K | +23.3% | +16.1% | +18.6% |
| ABUS | SELL | 2021-02-09 | 2021-02-10 | $5.00 | $100K | -13.2% | -14.1% | -37.6% |
| ABUS | SELL | 2020-12-14 | 2020-12-16 | $5.00 | $200K | -31.1% | -23.0% | -25.0% |
| ABUS | SELL | 2020-07-23 | 2020-07-27 | $5.01 | $100K | +8.2% | -27.5% | -30.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.